University of Alabama at Birmingham，IDS Pharmacy

Birmingham, Alabama 35294

2 studies enrolling now · 8 studies all time

What they study most

ALK-positive Advanced NSCLC, Breast Cancer Metastatic, Cancer of the Prostate, Carcinoma, Non-Small-Cell Lung, Endometrial Cancer, Endometrial Neoplasms, Esophageal Squamous Cell Carcinoma, Gastric Cancer, HER2 Positive Breast Cancer, Hepatocellular Carcinoma, Hormone Sensitive Prostate Cancer, Non-Small Cell Lung Cancer Metastatic

Studies at this site

• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients — Stopped early
• A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer — Stopped early
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer — Stopped early